Dextromethorphan and guaifenesin use needs to be monitored carefully in people with "weak metabolizer" CYP2D6 enzyme ranges and patients that are sedated. This combination medication provides a huge median poisonous dose (TD50) to median powerful dose (ED50) ratio (or therapeutic index) in these patients. 资助维基百科 外观 创建账号 登录 个人工具 创建账号 https://social-medialink.com/story3529681/the-5-second-trick-for-dextromethorphan-dxm-for-sale-in-australia